- Home
- RARE vs FINV Comparison
RARE vs FINV Comparison
Compare RARE & FINV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- FINV
- Stock Information
- Founded
- RARE 2010
- FINV 2007
- Country
- RARE United States
- FINV China
- Employees
- RARE N/A
- FINV N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- FINV Finance: Consumer Services
- Sector
- RARE Health Care
- FINV Finance
- Exchange
- RARE Nasdaq
- FINV Nasdaq
- Market Cap
- RARE 2.6B
- FINV 2.3B
- IPO Year
- RARE 2014
- FINV N/A
- Fundamental
- Price
- RARE $29.96
- FINV $8.25
- Analyst Decision
- RARE Strong Buy
- FINV Strong Buy
- Analyst Count
- RARE 14
- FINV 2
- Target Price
- RARE $86.64
- FINV $11.55
- AVG Volume (30 Days)
- RARE 1.4M
- FINV 2.3M
- Earning Date
- RARE 08-05-2025
- FINV 08-20-2025
- Dividend Yield
- RARE N/A
- FINV 3.43%
- EPS Growth
- RARE N/A
- FINV 32.63
- EPS
- RARE N/A
- FINV 1.49
- Revenue
- RARE $610,159,000.00
- FINV $1,927,901,951.00
- Revenue This Year
- RARE $19.72
- FINV $13.45
- Revenue Next Year
- RARE $23.29
- FINV $9.59
- P/E Ratio
- RARE N/A
- FINV $5.61
- Revenue Growth
- RARE 26.77
- FINV 7.84
- 52 Week Low
- RARE $25.81
- FINV $5.14
- 52 Week High
- RARE $60.37
- FINV $11.08
- Technical
- Relative Strength Index (RSI)
- RARE 53.11
- FINV 38.79
- Support Level
- RARE $29.04
- FINV $8.40
- Resistance Level
- RARE $30.61
- FINV $9.73
- Average True Range (ATR)
- RARE 0.80
- FINV 0.39
- MACD
- RARE 0.31
- FINV -0.05
- Stochastic Oscillator
- RARE 79.81
- FINV 2.32
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About FINV FinVolution Group
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.